You are here

Cellectar

Cellectar Reports 33% Overall Response Rate in Phase 2 Interim Data for CLR 131 in Relapsed/Refractory DLBCL Patients

CP Wire

Wed, 07/18/18 - 10:54 am

diffuse large B-cell lymphoma

Cellectar Reports 33% Overall Response Rate in Phase 2 Interim Data for CLR 131 in Relapsed/Refractory DLBCL Patients

Wed, 07/18/18 - 09:58 am

diffuse large B-cell lymphoma

Cellectar Granted Orphan Drug Designation for CLR 131 to Treat Rhabdomyosarcoma

CP Wire

Thu, 05/10/18 - 11:08 pm

rhabdomyosarcoma

Cellectar Granted Orphan Drug Designation for CLR 131 to Treat Rhabdomyosarcoma

Thu, 05/10/18 - 10:58 pm

rhabdomyosarcoma

6 Biopharma Movers Making a Run on Wednesday

24/7 Wall St

Wed, 06/15/16 - 05:50 pm

Infinity Pharma

6 Biotechs Seriously on the Move

24/7 Wall St

Fri, 06/3/16 - 10:47 am

Eleven Biotherapeutics

Repros Therapeutics